US dispute panel unused since LifeCore Biomedical
This article was originally published in Clinica
No companies have requested a meeting with the FDA's device dispute resolution panel since LifeCore Biomedical stepped forward as the first guinea pig for that process last September. That surprises Les Weinstein, ombudsman for FDA's Center for Devices and Radiological Health, because the panel recommended that FDA reverse its earlier position and approve LifeCore's PMA for an adhesion protection gel.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.